Poly Medicure Limited — Investor Meet, 13-05-2025: Analysts/Institutional Investor Meet/Con. Call Updates

Poly Medicure posted Q4 revenue growth of 16.5% YoY to Rs. 440 Cr with EBITDA margin rising to 27.1% and PAT at Rs. 91.8 Cr. Annual revenue grew ~21.5% to Rs. 1,670 Cr, with EBITDA of Rs. 451 Cr and PAT of Rs. 339 Cr. Domestic business grew 18.6%, led by 60% growth in Renal (Rs. 150 Cr+), targeting 50% CAGR by FY26 supported by new dialysis machine sales. Critical Care aims to more than double, and Cardiology launched new products soon. Exports expected to grow 12-15% amid global uncertainties, with stable 25-27% EBITDA margins. Rs. 500 Cr CAPEX planned for expanding manufacturing and R&D, focusing on Renal, Critical Care, and Cardiology. Domestic dialyzer market share is 10-12%, targeting 15-17%. The company holds strong liquidity and is open to M&A, maintaining a cautiously optimistic outlook centered on innovation and capacity growth.